111 related articles for article (PubMed ID: 9537195)
21. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
22. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
23. Extranodal malignant lymphoma: detection with FDG PET versus CT.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Merkle E; Frickhofen N; Reske SN
Radiology; 1998 Feb; 206(2):475-81. PubMed ID: 9457202
[TBL] [Abstract][Full Text] [Related]
24. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT.
Kubota K; Yokoyama J; Yamaguchi K; Ono S; Qureshy A; Itoh M; Fukuda H
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):590-5. PubMed ID: 14722678
[TBL] [Abstract][Full Text] [Related]
25. Dichotomy between Tc-99m MDP bone scan and fluorine-18 fluorodeoxyglucose coincidence detection positron emission tomography in patients with non-Hodgkin's lymphoma.
Lee J; Park CH; Kim HC; Kim HS
Clin Nucl Med; 2000 Jul; 25(7):532-5. PubMed ID: 10885695
[TBL] [Abstract][Full Text] [Related]
26. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
27. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
28. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma.
Cremerius U; Fabry U; Neuerburg J; Zimny M; Osieka R; Buell U
Nucl Med Commun; 1998 Nov; 19(11):1055-63. PubMed ID: 9861622
[TBL] [Abstract][Full Text] [Related]
30. Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas.
Kumar R; Maillard I; Schuster SJ; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1083-100. PubMed ID: 15488559
[TBL] [Abstract][Full Text] [Related]
31. Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission--a randomized trial of routine surveillance imaging procedures.
Picardi M; Pugliese N; Cirillo M; Zeppa P; Cozzolino I; Ciancia G; Pettinato G; Salvatore C; Quintarelli C; Pane F
Radiology; 2014 Jul; 272(1):262-74. PubMed ID: 24708193
[TBL] [Abstract][Full Text] [Related]
32. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
Bar-Shalom R
Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
[TBL] [Abstract][Full Text] [Related]
33. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
Cremerius U; Fabry U; Kröll U; Zimny M; Neuerburg J; Osieka R; Büll U
Nuklearmedizin; 1999; 38(1):24-30. PubMed ID: 9987778
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic value of 18F-FDG positron emission tomography in the early evaluation of the efficiency of treatment in patients with non-Hodgkin lymphomas].
Khodzhibekova MM; Tiutin LA; Kostenikov NA; Il'in NV; Vinogradova IuN
Vestn Rentgenol Radiol; 2014; (4):38-41. PubMed ID: 25775886
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
36. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
Even-Sapir E; Lievshitz G; Perry C; Herishanu Y; Lerman H; Metser U
Radiol Clin North Am; 2007 Jul; 45(4):697-709, vii. PubMed ID: 17706534
[TBL] [Abstract][Full Text] [Related]
37. Sciatic nerve neurolymphomatosis - extent and therapy response assessment with PET/CT.
Strobel K; Fischer K; Hany TF; Poryazova R; Jung HH
Clin Nucl Med; 2007 Aug; 32(8):646-8. PubMed ID: 17667443
[TBL] [Abstract][Full Text] [Related]
38. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
40. Baseline and ongoing PET-derived factors predict detrimental effect or potential utility of 18F-FDG PET/CT (FDG-PET/CT) performed for surveillance in asymptomatic lymphoma patients in first remission.
Morbelli S; Capitanio S; De Carli F; Bongioanni F; De Astis E; Miglino M; Verardi MT; Buschiazzo A; Fiz F; Marini C; Pomposelli E; Sambuceti G
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):232-239. PubMed ID: 26283504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]